关键词: 5-FU Fluorouracil Mohs micrographic surgery Recurrence Squamous cell carcinoma Squamous cell carcinoma in-situ

Mesh : Humans Fluorouracil / administration & dosage therapeutic use Male Female Aged Retrospective Studies Middle Aged Skin Neoplasms / drug therapy pathology diagnosis Carcinoma, Squamous Cell / drug therapy pathology diagnosis Chemotherapy, Adjuvant / methods Aged, 80 and over Treatment Outcome Mohs Surgery Antimetabolites, Antineoplastic / administration & dosage therapeutic use Carcinoma in Situ / drug therapy pathology Administration, Topical Follow-Up Studies Neoplasm Recurrence, Local / prevention & control Administration, Cutaneous

来  源:   DOI:10.1007/s00403-024-02906-4

Abstract:
Cutaneous squamous cell carcinoma in-situ (SCCis) is an intraepithelial tumor with a good prognosis. Standard treatment includes both surgical and non-surgical interventions. We determined the clearance rate for SCCis and residual SCCis identified on frozen section during Mohs micrographic surgery (MMS) after treatment with topical fluorouracil 5% cream (5-FU). All MMS cases were initiated for biopsy-proven invasive squamous cell carcinoma (SCC). A retrospective chart review was conducted from January 2017-February 2024 at Columbia University Irving Medical Center (CUIMC) to identify patients with SCCis who were treated with topical 5-FU as primary therapy or adjuvant therapy (AT) for residual SCCis post-MMS for invasive SCC. 41 patients were included (80% males, 70.1 ± 11.8 years). The average follow-up time for the primary therapy group was 25.4 ± 12.8 months, and for the post-MMS AT group 22.5 ± 11.1 months. In the group treated with topical 5-FU as primary therapy (n = 28), 27 patients (96.43%, 95% confidence interval: 81.65-99.91%) achieved complete clearance. One patient had recurrence at 8 months post-treatment. Of the patients in the post-MMS adjuvant treatment group (n = 13), 12 (92.3% clearance, 95% confidence interval 63.97-99.81%) achieved complete clearance. One patient had recurrence at 8 months post-treatment. This study found that topical 5-FU cream is effective as both primary therapy for SCCis and as adjuvant therapy for residual SCCis following MMS of invasive SCC.
摘要:
皮肤鳞状细胞原位癌(SCCis)是一种预后良好的上皮内肿瘤。标准治疗包括手术和非手术干预。我们确定了用5%氟尿嘧啶乳膏(5-FU)局部治疗后,在Mohs显微手术(MMS)期间在冷冻切片上发现的SCC和残留SCC的清除率。所有MMS病例均为活检证实的浸润性鳞状细胞癌(SCC)。2017年1月至2024年2月,在哥伦比亚大学欧文医学中心(CUIMC)进行了回顾性图表审查,以确定接受局部5-FU作为主要治疗或辅助治疗(AT)治疗的SCCis患者MMS后残留SCCis用于侵入性SCC。纳入41例患者(80%为男性,70.1±11.8年)。主要治疗组平均随访时间为25.4±12.8个月,MMS后AT组22.5±11.1个月。在以局部5-FU作为主要疗法治疗的组中(n=28),27例患者(96.43%,95%置信区间:81.65-99.91%)达到完全清除率。一名患者在治疗后8个月复发。在MMS后辅助治疗组的患者中(n=13),12(92.3%间隙,95%置信区间63.97-99.81%)实现完全清除率。一名患者在治疗后8个月复发。这项研究发现,局部5-FU乳膏既可以有效地作为SCCis的主要疗法,也可以作为侵袭性SCCMMS后残留SCCis的辅助疗法。
公众号